SciSparc Submits IND Application To FDA For Phase IIb Trial Of SCI-110 In Tourette Syndrome Treatment
Portfolio Pulse from Benzinga Newsdesk
SciSparc has submitted an Investigational New Drug (IND) application to the FDA for a Phase IIb trial of their drug SCI-110, aimed at treating Tourette Syndrome. This marks a significant step in the development of their treatment pipeline.
September 18, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc's submission of an IND application to the FDA for SCI-110 is a crucial step in advancing their treatment for Tourette Syndrome. This could potentially lead to further clinical trials and eventual market approval.
The submission of an IND application is a significant regulatory milestone that indicates progress in SciSparc's drug development process. If approved, it could lead to further clinical trials, which are essential for eventual market approval. This news is likely to positively impact SciSparc's stock price in the short term as it reflects advancement in their product pipeline.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90